BioLife Solutions, Inc. (BLFS) P/E Ratio History
Historical price-to-earnings valuation from 2002 to 2021
Loading P/E history...
BLFS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, BioLife Solutions, Inc. (BLFS) trades at a price-to-earnings ratio of -87.0x, with a stock price of $21.75 and trailing twelve-month earnings per share of $-0.25.
The current P/E is 143% below its 5-year average of 201.2x. Over the past five years, BLFS's P/E has ranged from a low of 1.3x to a high of 901.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, BLFS trades at a 493% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, BLFS trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BLFS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BLFS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $637M | 9.1Lowest | - | +163% | |
| $7B | 146.2 | - | +287%Best | |
| $5B | 96.6 | 64.72 | +104% | |
| $4B | 31.1 | 3.56Best | -16% | |
| $176B | 26.7 | 12.62 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BLFS Historical P/E Data (2002–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q3 | $42.32 | $0.09 | 486.4x | +142% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $44.51 | $0.05 | 901.0x | +348% |
| FY2020 Q4 | $39.89 | $0.25 | 157.7x | -22% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $28.94 | $0.34 | 84.1x | -58% |
| FY2020 Q2 | $16.35 | $0.73 | 22.4x | -89% | |
| FY2020 Q1 | $9.50 | $1.45 | 6.5x | -97% | |
| FY2018 Q4 | Mon Dec 31 2018 00:00:00 GM | $12.03 | $0.12 | 97.2x | -52% |
| FY2018 Q3 | Sun Sep 30 2018 00:00:00 GM | $17.50 | $0.04 | 452.2x | +125% |
| FY2003 Q1 | Mon Mar 31 2003 00:00:00 GM | $1.68 | $1.31 | 1.3x | -99% |
| FY2002 Q4 | $1.68 | $1.26 | 1.3x | -99% | |
| FY2002 Q3 | Mon Sep 30 2002 00:00:00 GM | $1.96 | $0.65 | 3.0x | -99% |
Average P/E for displayed period: 201.2x
See BLFS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BLFS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BLFS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBLFS — Frequently Asked Questions
Quick answers to the most common questions about buying BLFS stock.
Is BLFS stock overvalued or undervalued?
BLFS trades at -87.0x P/E, below its 5-year average of 201.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does BLFS's valuation compare to peers?
BioLife Solutions, Inc. P/E of -87.0x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is BLFS's PEG ratio?
BLFS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2002-2021.